Multiple sclerosis: long-term outcomes in ethnic minorities. analysis of a UK population-based registry by Alsaeed, Meshari et al.
Multiple sclerosis: Long-term outcomes in ethnic minorities with MS: analysis of a UK 
population-based registry. 
Meshari O Alsaeed1, Katharine E Harding1;2;3, Owain H Williams1;2, Mark D Willis1;2, James 
Hrastelj1;2, Emma C Tallantyre2, Fady G Joseph3, Mark Wardle2, Trevor P Pickersgill2, Neil P 
Robertson1;2 
 
1: Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University 
Hospital of Wales, Heath Park, Cardiff CF14 4XW 
 
2: Helen Durham Centre for Neuroinflammatory Disease, Department of Neurology, University 
Hospital of Wales, Heath Park, Cardiff CF14 4XW 
 
3: Department of Neurology, Royal Gwent Hospital, Cardiff Road, Newport, NP20 2UB 
 
 
 
 
Corresponding author 
Dr Katharine Harding 
Institute for Psychological Medicine and Clinical Neuroscience, 
Cardiff University 
University Hospital of Wales, 
Heath Park, 
Cardiff CF14 4XW, 
United Kingdom 
Telephone: +44 (0)2920 743454 
E-mail: katharineharding@doctors.org.uk 
 
 
Word count: abstract 188, manuscript 1493 
Keywords: multiple sclerosis, epidemiology  
 Abstract 
Background: Multiple sclerosis (MS) is most frequent in Caucasian populations. However, 
studies of MS in other ethnic groups may offer unique insights into genetic and 
environmental influences on disease, and data on long-term outcomes in these patients is 
limited. We have investigated clinical features and time to disability milestones in ethnic 
minority (EM) patients with MS in a UK population and made comparisons to a Caucasian 
cohort from the same region. 
 
Methods: 1949 MS patients (1866 Caucasian, 83 EM) were identified from a regional 
disease registry. Cox proportional hazards regression was used to analyse time to EDSS 
3.0, 4.0 and 6.0. 
 
Results: EM patients were younger at disease onset (28.6 years versus 32.8 years, p=0.001), 
and PPMS was less common (EM: 4.8%, Caucasian: 11.6%, p=0.03). After correction for 
clinical variables, ethnicity was associated with time to EDSS 3.0 (EM: hazard ratio [HR] 
1.75, p<0.0001) and 4.0 (HR 1.46, p=0.03), but not 6.0 (HR 1.5, p=0.05). 
 
Conclusions: EM patients reach early levels of fixed disability more rapidly than Caucasian 
patients, but this effect diminishes at later stages of disease. This has implications for 
clinical management of these patients. 
  
Introduction 
Multiple sclerosis (MS) is most common in Caucasian populations. A few studies have attempted 
to examine MS in ethnic minority (EM) groups but have struggled to make effective 
comparisons because of small patient numbers, lack of comparative data, limited follow-up and 
additional confounding factors. In addition, analysis[1–10] has focused on early phases of 
disease,[1] cross-sectional analysis,[2,8–10] or specific subgroups.[3,5] Few have examined 
long-term outcomes,[4,6,7] and none of these have compared with a geographically matched 
Caucasian population. However, differences in disease frequency and phenotype may provide 
key insights into disease aetiology and disease trajectory. We have examined patterns of early 
disease and long-term outcomes in EM and Caucasian patients from a well-described population-
based cohort from the United Kingdom. 
 
Methods 
Patient selection 
The southeast Wales MS registry was established in 1985 from a cross sectional study[11] with 
prospective longitudinal data collected since 1999. Patients were included if they had a diagnosis 
of MS, ethnicity was recorded, and prospectively collected longitudinal data was available from 
disease onset, including relapses, disease course, and Expanded Disability Status Scale 
(EDSS)[12] scores. EM patients were also classified by place of birth. The South East Wales 
Ethics Committee approved the study (reference number 05/WSE03/111) and written informed 
consent is obtained from all patients. 
 
Statistical analysis 
Demographics and clinical features at disease onset were compared using chi-squared tests, 
Student’s t test and one-way ANOVA. Time to EDSS 3.0, 4.0 and 6.0 was analysed using Cox 
proportional hazards regression, adjusting for age at onset, sex, and initial disease course. All 
analyses were undertaken using SPSS version 21. 
 
Results 
Demographics and clinical features 
1866 Caucasian and 83 EM patients were identified (22 Afro-Caribbean, 48 Asian, and 13 
Middle Eastern). 27 EM patients were born in Europe and 35 elsewhere. Country of birth was 
not available in 21. 
 
Male:female ratio was similar in both groups (EM: 1.7:1, Caucasian: 2.3:1, p=0.10). EM patients 
were younger at disease onset (28.6 years versus 32.8 years, p=0.001). There was no difference 
in demographic features between EM subgroups or by country of birth. 
 
PPMS was less common in EM patients (EM: 4.8%, Caucasian: 11.6%, p=0.03).There was no 
difference in annualised relapse rates (EM: 0.65, Caucasian: 0.55, p=0.08), or for symptoms at 
disease onset (Figure 1). No difference was identified for any clinical features between EM 
subgroups or by country of birth. 
 
Prognosis 
50 EM and 1417 Caucasian patients reached EDSS 3, 39 EM and 1313 Caucasian patients 
reached EDSS 4.0, and 28 EM and 1048 Caucasian patients reached EDSS 6.0.    Age at onset 
was associated with all endpoints, and disease course with time to EDSS 4.0 and 6.0.  Ethnicity 
was associated with time to EDSS 3.0 (EM: hazard ratio [HR] 1.8 (1.3 – 2.3), p<0.0001), and 4.0 
(EM: HR 1.5 (1.0–2.0), p=0.03). However this effect was not significant for time to EDSS 6.0 
(EM: HR 1.5 (0.99–2.2), p=0.05)(Table 1). 
 
 
Discussion 
In this study we have identified a younger age at onset and reduced frequency of PPMS in EM 
patients, with no differences observed in other presenting features. We also identified differences 
by ethnicity in reaching EDSS 3.0 and EDSS 4.0, although this effect did not persist in later 
stages of disease. 
 
The reason for the difference in outcomes is not clear, but could be genetic or environmental, or 
a combination of the two. It may also reflect variation in socioeconomic status, particularly for 
immigrants. The fact that the differences seen were limited to the earlier phases of disease is 
intriguing although larger studies are needed to confirm whether this was a power limitation at 
EDSS 6. 
 
Early studies suggested a poorer outcome for African Americans with MS,[1,2,5] but these 
studies were limited by cross-sectional analysis methods and the inclusion of patients with 
optico-spinal MS, before neuromyelitis optica was recognised as a separate disease. More recent 
studies have found a time to EDSS 6.0 of 22 years in Hong Kong Chinese,[6] 25 years in 
Lebanese[4] and 26 years in Brazilian patients,[7] which are at the upper end of estimates in 
Caucasian populations.[13] Additionally a recent comparative study of Japanese and British 
patients with MS has shown a reduced frequency of PPMS and a lower MS severity score 
(MSSS) in Japanese patients, implying a better outcome than in British patients.[10] 
 
For future studies, detailed data on family ancestry and geographical origin may be informative 
with regards to potential genetic admixing with different European populations, particularly in 
those of Afro-Caribbean descent.  This information was not available for our cohort but would be 
of value in future studies. 
 
Limitations of our study included the inability to examine outcomes in specific ethnic sub-groups 
as a result of limited patient numbers, the representation of only three EM groups and the lack of 
detailed long-term outcomes at very high disability score (i.e. EDSS 8.0 and death) which may 
have been informative. Defining differences in outcomes would clearly be of value in informing 
patient management in EM but is only likely to be achieved by the interrogation of very large 
combined datasets and would be an important future direction of research. 
 
In conclusion, our study suggests that presenting features for patients with MS residing in a 
common geographical location is similar across ethnic groups. However, EM patients present 
earlier and accumulate early disability more rapidly than their Caucasian counterparts. These 
observations may be of importance for disease management in EM patients, in particular when 
considering early efficacy of disease-modifying therapies. 
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Figures 
Figure 1: Symptoms at disease onset 
 
 
 
 
 
 
 
 
 
Tables 
Table 1: Cox proportional hazards regression model 
 
Clinical 
variable 
EDSS 3.0 EDSS 4.0 EDSS 6.0 
HR (95% CI) p HR (95% CI) p HR (95% CI) p 
Ethnicity: 
  Caucasian 
  EM 
 
 
Reference 
1.75  
(1.32–2.33) 
 
 
<0.001 
 
Reference 
1.46  
(1.05–2.02) 
 
 
0.026 
 
Reference 
1.47  
(0.99–2.16) 
 
 
0.05 
Age at 
onset 
1.04  
(1.04–1.05) 
<0.001 1.04  
(1.04–1.05) 
<0.001 1.05  
(1.04–1.06) 
<0.001 
Sex 0.97  
(0.86–1.08) 
0.54 0.96  
(0.85–1.09) 
0.54 0.96  
(0.84–1.10) 
0.52 
Disease 
course 
0.85  
(0.72–1.00) 
0.05 0.74  
(0.62–0.88) 
0.001 0.58  
(0.48–0.69) 
<0.001 
 
